This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cha, R.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cha, R.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2003, p. 1984-1987, Vol. 47, No. 6
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.6.1984-1987.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Linezolid and Vancomycin, Alone and in Combination with Rifampin, Compared with Moxifloxacin against a Multidrug-Resistant and a Vancomycin-Tolerant Streptococcus pneumoniae Strain in an In Vitro Pharmacodynamic Model

Raymond Cha1 and Michael J. Rybak1,2*

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences,1 School of Medicine, Wayne State University, Detroit Receiving Hospital, Detroit, Michigan2

Received 17 May 2002/ Returned for modification 8 January 2003/ Accepted 7 March 2003

Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log10 CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae.

* Corresponding author. Mailing address: Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Rm. 4148, 259 Mack Ave., Detroit, MI 48201. Phone: (313) 993-4376. Fax: (313) 557-8915. E-mail: m.rybak{at}wayne.edu.

Antimicrobial Agents and Chemotherapy, June 2003, p. 1984-1987, Vol. 47, No. 6
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.6.1984-1987.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Boak, L. M., Li, J., Rayner, C. R., Nation, R. L. (2007). Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro Model. Antimicrob. Agents Chemother. 51: 1287-1292 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»